Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Slides:

Advertisements

Similar presentations

What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.

Advertisements

Questions Diabetes. 48. NIDDM response The figure below shows the ‘normal’ response of blood glucose (solid line) and insulin (dashed line) concentrations.

Conditions associated with insulin resistance

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

©1999, Medical Age Publishing, Division of Snyder Healthcare Communications Worldwide, Stamford, Connecticut. All rights reserved. Epidemiology and Diagnosis.

Natural History of Type 2 Diabetes Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota. ObesityIFG*DiabetesUncontrolled Hyperglycemia.

TEMPLATE DESIGN © CONTINUOUS GLUCOSE MONITORING, ORAL GLUCOSE TOLERANCE, AND INSULIN – GLUCOSE PARAMETERS IN ADOLESCENTS.

Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose Diabetes Division and the Clinical.

Journal Club 埼玉医科大学総合医療センター内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田昌文 Matsuda, Masafumi.

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

Anesthes. 2008;108(3): doi: /ALN.0b013e Figure Legend:

بايو كمستري (م 3) / د . احمد الطويل

GLUCOSE TOLERANCE TEST (GTT)

Independent variables (baseline) Loge (HOMA-IR) b P

Glucose tolerance testing. A

The oral glucose tolerance test (OGTT) revisited

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

The relationship of angiographically defined coronary artery disease with insulin sensitivity and secretion in subjects with different glucose tolerance

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Diabetes and Pregnancy

Nat. Rev. Nephrol. doi: /nrneph

Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus P.J. Palumbo, MD Mayo Clinic Proceedings Volume.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes Gani.

Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET) Adèle Coriati, Sophie Ziai, Mirna Azar, Yves.

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Insulin resistance in African Americans

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome

Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity? Valérie Boudreau, Adèle.

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Relationships between NEFA release from subcutaneous abdominal adipose tissue and fat mass (A) and fasting insulin (B) in different groups of subjects.

Odds of incident diabetes by OGTT insulin patterns according to subjects characterized by presence or absence of IGT or dichotomized at the median value.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Glucose tolerance in WT and TRPM2-KO mice.

The figure shows the mean±SD of glucose and insulin for the 2-hour OGTTs and MTTs for the 12 HP diet subjects and the 12 HC diets subjects. The figure.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG,

Cardiorespiratory fitness is associated with SiOGTT, GSISOGTT, and DIOGTT. VO2max was measured during incremental workload and exhaustive aerobic exercise.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Correlations between leptin DNA methylation and 2-h post-OGTT glucose levels, within the IGT group (A and B), leptin DNA methylation and mRNA levels (C.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2DM) as a function of the 2-hour plasma glucose (PG) concentration during the OGTT (see text for a more detailed discussion). ΔINS/ΔGLU = increment in plasma insulin concentration/increment in plasma glucose concentration during oral glucose tolerance testing. Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2DM) as a function of the 2-hour plasma glucose (PG) concentration during the OGTT (see text for a more detailed discussion). ΔINS/ΔGLU = increment in plasma insulin concentration/increment in plasma glucose concentration during oral glucose tolerance testing. The curves for lean and obese individuals are shown separately. IR = insulin resistance measured with the insulin clamp technique. Ralph A. DeFronzo et al. Diabetes Spectr 2014;27:100-112 ©2014 by American Diabetes Association